STOCK TITAN

Vigil Neuroscience, Inc. - $VIGL STOCK NEWS

Welcome to our dedicated page for Vigil Neuroscience news (Ticker: $VIGL), a resource for investors and traders seeking the latest updates and insights on Vigil Neuroscience stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vigil Neuroscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vigil Neuroscience's position in the market.

Rhea-AI Summary
Vigil Neuroscience, Inc. (Nasdaq: VIGL) extends projected cash runway into second half of 2025. The company is on track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in Q3 2024. The company presented at J.P. Morgan Healthcare Conference on January 11, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
none
-
Rhea-AI Summary
Vigil Neuroscience, Inc. (VIGL) to participate in fireside chat at Evercore ISI 6th Annual HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Vigil Neuroscience, Inc. (Nasdaq: VIGL) announced positive interim data from the Company’s Phase 2 IGNITE proof-of-concept clinical trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). The interim data demonstrated favorable safety and tolerability of iluzanebart, clear CNS target engagement, and downstream pharmacological activity at 20 mg/kg, with directionally supportive changes in individual patients at 6 months on MRI and NfL biomarkers. The Company expects to report Phase 2 IGNITE results from all patients in 20 mg/kg and 40 mg/kg cohorts at 6 months in the third quarter of 2024. Vigil will host a webinar to discuss the Phase 2 IGNITE interim data today at 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.03%
Tags
Rhea-AI Summary
Vigil Neuroscience, Inc. announced financial results for the third quarter, with a cash position of $133.6 million as of September 30, 2023. They provided updates on their ongoing clinical trials for VGL101 in ALSP and VG-3927 in Alzheimer's disease, including interim data from the IGNITE Phase 2 clinical trial of VGL101 on track for this quarter and the first participant dosed in the Phase 1 study of VG-3927.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.34%
Tags
-
Rhea-AI Summary
Vigil Neuroscience announces dosing of first participant in Phase 1 clinical trial for potential Alzheimer's treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.65%
Tags
-
Rhea-AI Summary
Vigil Neuroscience to participate in fireside chat at Jefferies Inaugural Biotech CNS/Neuro Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.18%
Tags
conferences
Rhea-AI Summary
Vigil Neuroscience receives positive opinion for orphan drug designation for VGL101 in EU for the treatment of CSF1R-related leukoencephalopathy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
-
Rhea-AI Summary
Vigil Neuroscience announces positive Phase 1 data analysis for VGL101, on track to report interim data from IGNITE trial in Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
-
Rhea-AI Summary
Vigil Neuroscience announces lead candidate for Alzheimer's Disease treatment, IND for VG-3927 now open, Phase 1 trial to proceed with partial clinical hold. Phase 1 dosing expected in October 2023. Company to host virtual R&D event on September 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Vigil Neuroscience to participate in fireside chat at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Vigil Neuroscience, Inc.

Nasdaq:VIGL

VIGL Rankings

VIGL Stock Data

130.98M
16.21M
9.32%
85.64%
2.68%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WATERTOWN

About VIGL

vigil neuroscience is the world’s first microglia-focused therapeutics company. our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. we are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.